Phase II clinical trial using anti-CD3 × anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer...

por Lum, Lawrence G., Al-Kadhimi, Zaid, Deol, Abhinav, Kondadasula, Vidya, Schalk, Dana, Tomashewski, Elyse, Steele, Patricia, Fields, Kristie, Giroux, Melissa, Liu, Qin, Flaherty, Lawrence, Simon, Michael, Thakur, Archana
Publicado 2021